Hepatitis c genotype 6: A concise review and response-guided therapy proposal

World Journal of Hepatology

Volumn 5, Issue 9, 2013, Pages 496-504

  Bunchorntavakul, Chalermrat ^a   Chavalitdhamrong, Disaya ^b   Tanwandee, Tawesak ^c  

^a RANGSIT UNIVERSITY   (Thailand)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Epidemiology; Genotype 6; Hepatitis c; Pegylated interferon; Response guided therapy; Ribavirin; Southeast asia; Treatment

Indexed keywords

EID: 84885815731     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v5.i9.496     Document Type: Short Survey

References (64)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29 Suppl 1: 74-81 [PMID: 19207969 DOI: 10.1111/j.1478-3231.2008.01934.x]
2. Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5 and 6. Clin Gastroenterol Hepatol 2005; 3: S97-S101 [PMID: 16234071]
3. Hepatitis C--global prevalence (update). Wkly Epidemiol Rec 1999; 74: 425-427 [PMID: 10645164]
4. Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, Amarapurkar D, Chen CH, Dou X, El Khayat H, Elshazly M, Esmat G, Guan R, Han KH, Koike K, Largen A, McCaughan G, Mogawer S, Monis A, Nawaz A, Piratvisuth T, Sanai FM, Sharara AI, Sibbel S, Sood A, Suh DJ, Wallace C, Young K, Negro F. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int ,2011, 31 Suppl 2: 61-80 [PMID: 21651703 DOI: 10.1111/ j.1478-3231.2011.02540.x]
5. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714 [PMID: 16702586]
6. Chao DT, Abe K, Nguyen MH. Systematic review: epidemiology of hepatitis C genotype 6 and its management. Aliment Pharmacol Ther 2011; 34: 286-296 [PMID: 21623850 DOI:10.1111/j.1365-2036.2011.04714.x]
7. Kanistanon D, Neelamek M, Dharakul T, Songsivilai S. Genotypic distribution of hepatitis C virus in different regions of Thailand. J Clin Microbiol 1997; 35: 1772-1776 [PMID: 9196191]
8. Sunanchaikarn S, Theamboonlers A, Chongsrisawat V, Yoocharoen P, Tharmaphornpilas P, Warinsathien P, Sinlaparatsamee S, Paupunwatana S, Chaiear K, Khwanjaipanich S, Poovorawan Y. Seroepidemiology and genotypes of hepatitis C virus in Thailand. Asian Pac J Allergy Immunol 2007; 25: 175-182 [PMID: 18035806]
9. Jutavijittum P, Jiviriyawat Y, Yousukh A, Pantip C, Maneekarn N, Toriyama K. Genotypic distribution of hepatitis C virus in voluntary blood donors of northern Thailand. Southeast Asian J Trop Med Public Health 2009; 40: 471-479 [PMID: 19842432]
10. Akkarathamrongsin S, Praianantathavorn K, Hacharoen N, Theamboonlers A, Tangkijvanich P, Tanaka Y, Mizokami M, Poovorawan Y. Geographic distribution of hepatitis C virus genotype 6 subtypes in Thailand. J Med Virol 2010; 82: 257-262 [PMID: 20029811 DOI:10.1002/jmv.21680]
11. Shinji T, Kyaw YY, Gokan K, Tanaka Y, Ochi K, Kusano N, Mizushima T, Fujioka S, Shiraha H, Lwin AA, Shiratori Y, Mizokami M, Khin M, Miyahara M, Okada S, Koide N. Analysis of HCV genotypes from blood donors shows three new HCV type 6 subgroups exist in Myanmar. Acta Med Okayama 2004; 58: 135-142 [PMID: 15471435]
12. Lwin AA, Shinji T, Khin M, Win N, Obika M, Okada S, Koide N. Hepatitis C virus genotype distribution in Myanmar: Predominance of genotype 6 and existence of new genotype 6 subtype. Hepatol Res 2007; 37: 337-345 [PMID: 17441806]
13. Nyuyen MH, Trinh H, Garcia RT, Ning J, Keeffe EB. High Prevalence of Novel Genotypes in Vietnamese Patients with Chronic Hepatitis C. Gastroenterology 2004; 126 (4 Suppl 2): 742A
14. Pham DA, Leuangwutiwong P, Jittmittraphap A, Luplertlop N, Bach HK, Akkarathamrongsin S, Theamboonlers A, Poovorawan Y. High prevalence of Hepatitis C virus genotype 6 in Vietnam. Asian Pac J Allergy Immunol 2009; 27: 153-160 [PMID: 19839502]
15. Mauss S, Berger F, Vogel M, Pfeiffer-Vornkahl H, Alshuth U, Rockstroh JK, Niederau C, Hüppe D. Treatment results of chronic hepatitis C genotype 5 and 6 infections in Germany. Z Gastroenterol 2012; 50: 441-444 [PMID: 22581697 DOI:10.1055/s-0031-1282072]
16. Oluboyede OA, Topley E, Ogunbode O. Iron deficiency in pregnant women in Ibarapa District of Western Nigeria. Br J Haematol 1977; 36: 527-531 [PMID: 889718]
17. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-973 [PMID: 16149085]
18. Nguyen LH, Nguyen MH. Systematic review: Asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther 2013; 37: 921-936 [PMID: 23557103 DOI:10.1111/apt.12300]
19. Bouchardeau F, Cantaloube JF, Chevaliez S, Portal C, Razer A, Lefrére JJ, Pawlotsky JM, De Micco P, Laperche S. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol 2007; 45: 1140-1145 [PMID: 17251399]
20. Noppornpanth S, Sablon E, De Nys K, Truong XL, Brouwer J, Van Brussel M, Smits SL, Poovorawan Y, Osterhaus AD, Haagmans BL. Genotyping hepatitis C viruses from Southeast Asia by a novel line probe assay that simultaneously detects core and 5' untranslated regions. J Clin Microbiol 2006; 44: 3969-3974 [PMID: 16957039]
21. Verbeeck J, Stanley MJ, Shieh J, Celis L, Huyck E, Wollants E, Morimoto J, Farrior A, Sablon E, Jankowski-Hennig M, Schaper C, Johnson P, Van Ranst M, Van Brussel M. Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0. J Clin Microbiol 2008; 46: 1901-1906 [PMID: 18400913 DOI:10.1128/JCM.02390-07]
22. Hübschen JM, Jutavijittum P, Thammavong T, Samountry B, Yousukh A, Toriyama K, Sausy A, Muller CP. High genetic diversity including potential new subtypes of hepatitis C virus genotype 6 in Lao People's Democratic Republic. Clin Microbiol Infect 2011; 17: E30-E34 [PMID: 21958219 DOI:10.1111/j.1469-0691.2011.03665.x]
23. Akkarathamrongsin S, Praianantathavorn K, Hacharoen N, Theamboonlers A, Tangkijvanich P, Poovorawan Y. Seroprevalence and genotype of hepatitis C virus among immigrant workers from Cambodia and Myanmar in Thailand. Intervirology 2011; 54: 10-16 [PMID: 20689311 DOI:10.1159/000318884]
24. Lu L, Nakano T, He Y, Fu Y, Hagedorn CH, Robertson BH. Hepatitis C virus genotype distribution in China: predominance of closely related subtype 1b isolates and existence of new genotype 6 variants. J Med Virol 2005; 75: 538-549 [PMID: 15714489]
25. Prescott LE, Simmonds P, Lai CL, Chan NK, Pike I, Yap PL, Lin CK. Detection and clinical features of hepatitis C virus type 6 infections in blood donors from Hong Kong. J Med Virol 1996; 50: 168-175 [PMID: 8915883]
26. Zhou DX, Tang JW, Chu IM, Cheung JL, Tang NL, Tam JS, Chan PK. Hepatitis C virus genotype distribution among intravenous drug user and the general population in Hong Kong. J Med Virol 2006; 78: 574-581 [PMID: 16555294]
27. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264 [PMID: 21371579 DOI:10.1016/j.jhep.2011.02.023]
28. Nguyen NH, Vutien P, Trinh HN, Garcia RT, Nguyen LH, Nguyen HA, Nguyen KK, Nguyen MH. Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans. Hepatol Int 2010; 4: 523-529 [PMID: 20827411 DOI:10.1007/s12072-010-9181-7]
29. Wong DA, Tong LK, Lim W. High prevalence of hepatitis C virus genotype 6 among certain risk groups in Hong Kong. Eur J Epidemiol 1998; 14: 421-426 [PMID: 9744672]
30. Seto WK, Lai CL, Fung J, Hung I, Yuen J, Young J, Wong DK, Yuen MF. Natural history of chronic hepatitis C: genotype 1 versus genotype 6. J Hepatol 2010; 53: 444-448 [PMID: 20554340 DOI: 10.1016/j.jhep.2010.04.009]
31. Lawson A. A comparison of the natural history and outcome of treatment for Asian and non-Asian hepatitis C-infected patients. J Viral Hepat 2011; 18: e270-e277 [PMID: 21138506 DOI:10.1111/j.1365-2893.2010.01406.x]
32. Ferri C, Antonelli A, Mascia MT, Sebastiani M, Fallahi P, Ferrari D, Pileri SA, Zignego AL. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig Liver Dis 2007; 39 Suppl 1: S13-S21 [PMID: 17936215]
33. Charles ED, Dustin LB. Hepatitis C virus-induced cryoglobulinemia. Kidney Int 2009; 76: 818-824 [PMID: 19606079 DOI:10.1038/ki.2009.247]
34. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374 [PMID: 19330875 DOI:10.1002/hep.22759]
35. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444 [PMID: 21898493 DOI:10.1002/hep.24641]
36. Dev AT, McCaw R, Sundararajan V, Bowden S, Sievert W. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology 2002; 36: 1259-1265 [PMID: 12395338]
37. Hui CK, Yuen MF, Sablon E, Chan AO, Wong BC, Lai CL. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. J Infect Dis 2003; 187: 1071-1074 [PMID: 12660921]
38. Fung J, Lai CL, Hung I, Young J, Cheng C, Wong D, Yuen MF. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. J Infect Dis 2008; 198: 808-812 [PMID: 18657036 DOI:10.1086/591252]
39. Thu-Thuy PT, Tan-Dat H. Pegylated interferon a-2a plus ribavirin in chronic hepatitis C patietns with genotype 6. Hepatol Int 2009; 3: abstract FP053
40. Nguyen NH, VuTien P, Garcia RT, Trinh H, Nguyen H, Nguyen K, Levitt B, Nguyen MH. Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2/3 vs 6. J Viral Hepat 2010; 17: 691-697 [PMID: 20002562 DOI:10.1111/j.1365-2893.2009.01226.x]
41. Tsang OT, Zee JS, Chan JM, Li RS, Kan YM, Li FT, Lo FH, Chow DA, Cheung KW, Chan KH, Yeung YW, Ng FH, Li MK, Kwan WK, Lai TS. Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1. J Gastroenterol Hepatol 2010; 25: 766-771 [PMID: 20492332 DOI:10.1111/j.1440-1746.2009.06163.x]
42. Zhou YQ, Wang XH, Hong GH, Zhu Y, Zhang XQ, Hu YJ, Mao Q. Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a. J Viral Hepat 2011; 18: 595-600 [PMID: 21105968 DOI: 10.1111/ j.1365-2893.2010.01373.x]
43. Cheng JT, Hsien C, Sun HE, Tong MJ. The emerging importance of chronic hepatitis C infection in Asian Americans. Am J Gastroenterol 2006; 101: 2737-2743 [PMID: 17227521]
44. Nguyen MH, Trinh HN, Garcia R, Nguyen G, Lam KD, Keeffe EB. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 wk versus 24 wk of peginterferon plus ribavirin. Am J Gastroenterol 2008; 103: 1131-1135 [PMID: 18477343 DOI: 10.1111/ j.1572-0241.2008.01793.x]
45. Lam KD, Trinh HN, Do ST, Nguyen TT, Garcia RT, Nguyen T, Phan QQ, Nguyen HA, Nguyen KK, Nguyen LH, Nguyen MH. Randomized controlled trial of pegylated interferon-a 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. Hepatology 2010; 52: 1573-1580 [PMID: 21038410 DOI: 10.1002/hep.23889]
46. Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafri W, Tateishi R, Hamid SS, Chuang WL, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao JH, McCaughan GW. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatology Int 2012; 6: 409-435 [DOI: 10.1007/s12072-012-9342-y]
47. Thu Thuy PT, Bunchorntavakul C, Tan Dat H, Rajender Reddy K. A randomized trial of 48 versus 24 wk of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C. J Hepatol 2012; 56: 1012-1018 [PMID: 22266603 DOI: 10.1016/j.jhep.2011.12.020]
48. Tangkijvanich P, Komolmit P, Mahachai V, Poovorawan K, Akkarathamrongsin S, Poovorawan Y. Response-guided therapy for patients with hepatitis C virus genotype 6 infection: a pilot study. J Viral Hepat 2012; 19: 423-430 [PMID: 22571904 DOI:10.1111/j.1365-2893.2011.01566.x]
49. Fancher TL, Ton H, Le Meyer O, Ho T, Paterniti DA. Discussing depression with Vietnamese American patients. J Immigr Minor Health 2010; 12: 263-266 [PMID: 19242803 DOI:10.1007/s10903-009-9234-y]
50. Vutien P, Nguyen NH, Trinh HN, Li J, Garcia RT, Garcia G, Nguyen KK, Nguyen HA, Levitt BS, Keeffe EB, Nguyen MH. Similar treatment response to peginterferon and ribavirin in Asian and Caucasian patients with chronic hepatitis C. Am J Gastroenterol 2010; 105: 1110-1115 [PMID: 19904247 DOI:10.1038/ajg.2009.635]
51. Schaefer M, Mauss S. Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects. Curr Drug Abuse Rev 2008; 1: 177-187 [PMID: 19630716]
52. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401 [PMID: 19684573 DOI:10.1038/nature08309]
53. Lange CM, Zeuzem S. IL28B single nucleotide polymorphisms in the treatment of hepatitis C. J Hepatol 2011; 55: 692-701 [PMID: 21440591 DOI:10.1016/j.jhep.2011.03.006]
54. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801 [PMID: 19759533 DOI:10.1038/nature08463]
55. Seto WK, Tanaka Y, Liu K, Lai CL, Yuen MF. The Effects of IL-28B and ITPA polymorphisms on treatment of hepatitis C virus genotype 6. Am J Gastroenterol 2011; 106: 1007-1008 [PMID: 21540909 DOI:10.1038/ajg.2011.40]
56. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81 [PMID: 8531962]
57. Zhou XM, Chan PK, Tam JS. Mutations around interferon sensitivity-determining region: a pilot resistance report of hepatitis C virus 1b in a Hong Kong population. World J Gastroenterol 2011; 17: 5317-5323 [PMID: 22219602 DOI:10.3748/wjg.v17.i48.5317]
58. Zhou DX, Chan PK, Zhang T, Tully DC, Tam JS. Sequence diversity of hepatitis C virus 6a within the extended interferon sensitivity-determining region correlates with interferon-alpha/ribavirin treatment outcomes. Virus Res 2010; 153: 44-49 [PMID: 20624431 DOI:10.1016/j.virusres.2010.07.004]
59. Hofgärtner WT, Polyak SJ, Sullivan DG, Carithers RL, Gretch DR. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b. J Med Virol 1997; 53: 118-126 [PMID: 9334922]
60. Zeuzem S, Lee JH, Roth WK. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon a. Hepatology 1997; 25: 740-744 [PMID: 9049228]
61. Clark VC, Peter JA, Nelson DR. New therapeutic strategies in HCV: second-generation protease inhibitors. Liver Int 2013; 33 Suppl 1: 80-84 [PMID: 23286850 DOI:10.1111/liv.12061]
62. Gerber L, Welzel TM, Zeuzem S. New therapeutic strategies in HCV: polymerase inhibitors. Liver Int 2013; 33 Suppl 1: 85-92 [PMID: 23286851 DOI:10.1111/liv.12068]
63. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Sofosbuvir with pegylated interferon a-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381: 2100-2107 [PMID: 23499440 DOI:10.1016/S0140-6736(13)60247-0]
64. Lenz O, Vijgen L, Berke JM, Cummings MD, Fevery B, Peeters M, De Smedt G, Moreno C, Picchio G. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatol 2013; 58: 445-451 [PMID: 23142061 DOI:10.1016/j.jhep.2012.10.028]